#GS3 #Science&Technology  

Bharat Biotech gained an edge in the race among a few entities in the country and several more globally to ready a vaccine for COVID-19 when the Drug Controller General of India (DCGI) cleared its product for human clinical trials. 

  • The collaboration with the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV) was instrumental in the development of the vaccine. The trials of Covaxin, the vaccine, will begin next month. 
  • The indigenous, inactivated vaccine has been developed and manufactured in Bharat Biotech’s Bio-Safety Level 3 (BSL-3) High Containment facility located in Hyderbad’s Genome Valley. 

‘National importance’ 

  • Bharat Biotech is committed to advancing vaccine development as a matter of national importance to demonstrate India’s strength in handling future pandemics. 
Print Friendly and PDF
blog comments powered by Disqus